

IP4 Rec'd PCT/PTO 12 JAN 2006

ARNOLD & PORTER LLP

202.942.5000  
202.942.5999 Fax

555 Twelfth Street, NW  
Washington, DC 20004-1206



January 12, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Application No. 10/531,415  
Filed: October 17, 2003  
Title: **Delocalization Molecules and Use Thereof**  
Applicants: Wolfgang E. BERDEL, *et al.*  
Atty. Docket: 20057.002

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. an Information Disclosure Statement;
2. a Form PTO-1449 (3 pages) with (29) cited references; and
3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 20057.002. A duplicate copy of this letter is enclosed.

Respectfully submitted,

*Rachel L. Adams*

David R. Marsh (Reg. No. 41,408)  
Rachel L. Adams (Reg. No. 54,660)

Attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wolfgang E. BERDEL, *et al.*

Group Art Unit: Not Yet Assigned

Appln. No.: 10/531,415

Examiner: Not Yet Assigned

Filed: October 17, 2003

Atty. Docket: 20057.002

For: **Delocalization Molecules and Use  
Thereof**

Confirm. No.: 2682

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

**CERTIFICATION AND/OR FEE**

Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.


Respectfully submitted,

*Rachel L. Adams*

David R. Marsh (Reg. No. 41,408)  
Rachel L. Adams (Reg. No. 54,660)

Date: January 12, 2006

ARNOLD & PORTER LLP  
555 Twelfth Street, N.W.  
Washington, D.C. 20004-1206  
(202) 942-5000 telephone  
(202) 942-5999 facsimile



FORM PTO-1449


## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 20057.002	APPLICATION NO. 10/531,415
APPLICANTS Wolfgang E. BERDEL <i>et al.</i>	
FILING DATE October 17, 2003	GROUP To be assigned

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA1	Bischoff, <i>et al.</i> , "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells", <u>Science</u> , Vol. 274, pp. 373-376 (1996)
AB1	Britos-Bray and Friedman, "Core Binding Factor Cannot Synergistically Activate the Myeloperoxidase Proximal Enhancer in Immature Myeloid Cells without c-Myb", <u>Molecular and Cellular Biology</u> , Vol. 17, No. 9, pp. 5127-5135 (1997)
AC1	Daley, <i>et al.</i> , "Induction of Chronic Myelogenous Leukemia in Mice by the P210 <sup>bcr/abl</sup> Gene of the Philadelphia Chromosome", <u>Science</u> , Vol. 247, pp. 824-830 (1990)
AD1	Darzynkiewicz, <i>et al.</i> , "Flow Cytometry in Analysis of Cell Cycle and Apoptosis", <u>Seminars in Hematology</u> , Vol. 38, No. 2, pp. 179-193 (2001)
AE1	Downing, "The AML1-ETO Chimaeric Transcription Factor in Acute Myeloid Leukaemia: Biology and Clinical Significance", <u>British Journal of Haematology</u> , Vol. 106, pp. 296-308 (1999)
AF1	Frank, <i>et al.</i> , "The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B", <u>Oncogene</u> , Vol. 11, pp. 2667-2674 (1995)
AG1	Gewirtz and Calabretta, "A c-myc Antisense Oligodeoxynucleotide Inhibits Normal Human Hematopoiesis in Vitro", <u>Science</u> , Vol. 242, pp. 1303-1306 (1988)
AH1	Gewirtz, "Myb targeted therapeutics for the treatment of human malignancies", <u>Oncogene</u> , Vol. 18, pp. 3056-3062 (1999)
AI1	Lenny, <i>et al.</i> , "Functional domains of the t(8;21) fusion protein, AML-1/ETO", <u>Oncogene</u> , Vol. 11, 1761-1769 (1995)
AJ1	Linggi, <i>et al.</i> , "The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14 <sup>ARF</sup> tumor suppressor in acute myeloid leukemia", <u>Nature Medicine</u> , Vol. 8, No. 7, pp. 743-750 (2002)
AK1	Mao, <i>et al.</i> , "Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias", <u>Molecular and Cellular Biology</u> , Vol. 19, No. 5, pp. 3635-3644 (1999)
AL1	McCormick, "Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015", <u>Seminars in Cancer Biology</u> , Vol. 10, pp. 453-459 (2000)
AM1	Meyers, <i>et al.</i> , "The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation", <u>Molecular and Cellular Biology</u> , Vol. 15, No. 4, pp. 1974-1982 (1995)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

 <p>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</p>		ATTY. DOCKET NO.	APPLICATION NO.
		20057.002	10/531,415
		APPLICANTS	
		Wolfgang E. BERDEL <i>et al.</i>	
		FILING DATE	GROUP
		October 17, 2003	To be assigned
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA2	Mizuki, <i>et al.</i> , "Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways", <u>Blood</u> , Vol. 96, No. 12, pp. 3907-3914 (2000)	
	AB2	Mucenski, <i>et al.</i> , "A Functional c-myb Gene Is Required for Normal Murine Fetal Hepatic Hematopoiesis", <u>Cell</u> , Vol. 65, pp. 677-689 (1991)	
	AC2	Müller, <i>et al.</i> , "c-myb Transactivates the Human Cyclin A1 Promoter and Induces Cyclin A1 Gene Expression", <u>Blood</u> , Vol. 94, No. 12, pp. 4255-4262 (1999)	
	AD2	Müller, <i>et al.</i> , "Methylation of the Cyclin A1 Promoter Correlates with Gene Silencing in Somatic Cell Lines, while Tissue-Specific Expression of Cyclin A1 is Methylation Independent", <u>Molecular and Cellular Biology</u> , Vol. 20, No. 9, pp. 3316-3329 (2000)	
	AE2	Müller-Tidow, <i>et al.</i> , "Redirection of Oncoproteins to Kill Cancer Cells", <u>Cell Cycle</u> , Vol. 2, No. 6, pp. 531-533 (2003)	
	AF2	Oelgeschläger, <i>et al.</i> , "C/EBP, c-Myb, and PU.1 Cooperate to Regulate the Neutrophil Elastase Promotor", <u>Molecular and Cellular Biology</u> , Vol. 16, No. 9, pp. 4717-4725 (1996)	
	AG2	Pabst, <i>et al.</i> , "AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia", <u>Nature Medicine</u> , Vol. 7, No. 4, pp. 444-451 (2001)	
	AH2	Ratajczak, <i>et al.</i> , "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 89, pp. 11823-11827 (1992)	
	AI2	Sakura, <i>et al.</i> , "Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 86, pp. 5758-5762 (1989)	
	AJ2	Steffen, <i>et al.</i> , "Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia", <u>PNAS</u> , Vol. 100, No. 14, pp. 8448-8453 (2003)	
	AK2	Stein, <i>et al.</i> , "Subnuclear Organization and Trafficking of Regulatory Proteins: Implications for Biological Control and Cancer", <u>Journal of Cellular Biochemistry</u> , Supplement 35, pp. 84-92 (2000)	
	AL2	Taylor, <i>et al.</i> , "A dominant interfering Myb mutant causes apoptosis in T cells", <u>Genes and Development</u> , Vol. 10, pp. 2732-2744 (1996)	
	AM2	Vigneri and Wang, "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase", <u>Nature Medicine</u> , Vol. 7, No. 2, pp. 228-234 (2001)	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

20057.002

APPLICATION NO.

10/531,415

APPLICANTS

Wolfgang E. BERDEL *et al.*

FILING DATE

October 17, 2003

GROUP

To be assigned

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA3

Wang, *et al.*, "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex", Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 10860-10865 (1998)

AB3

White and Weston, "Myb is required for self-renewal in a model system of early hematopoiesis", Oncogene, Vol. 19, pp. 1196-1205 (2000)

AC3

Ziebold, *et al.*, "Phosphorylation and activation of B-Myb by cyclin A-Cdk2", Current Biology, Vol. 7, No. 4, pp. 253-260 (1997)

AD3

AE3

AF3

AG3

AH3

AI3

AJ3

AK3

AL3

AM3

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.